ChromaDex to Participate in the LD Micro Invitational XIII
ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, are scheduled to present on June 6th at 1:30pm Pacific Time (4:30pm Eastern Time).
ChromaDex management will also attend virtual one-on-one meetings with institutional investors throughout the day. For those interested in having a meeting with ChromaDex, please visit www.ldmicro.com for more information.
We invite interested parties to watch ChromaDex’s live presentation via this webcast link: ChromaDex Investor Presentation – LD Micro Invitational
To view ChromaDex’s profile, please use this link: http://www.ldmicro.com/profile/CDXC
For additional information on ChromaDex, visit www.chromadex.com.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230530005227/en/
ChromaDex Media Contact:
Kendall Knysch, Director of Media Relations
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
+1 (949) 356-1620
InvestorRelations@ChromaDex.com
Source: ChromaDex Corporation
